       Document 0133
 DOCN  M9640133
 TI    Treatment strategies for epidemic Kaposi's sarcoma.
 DT    9604
 AU    Volm MD; von Roenn JH; Northwestern University Medical School, Chicago,
       Illinois, USA.
 SO    Curr Opin Oncol. 1995 Sep;7(5):429-36. Unique Identifier : AIDSLINE
       MED/96076278
 AB    As the AIDS epidemic progresses, Kaposi's sarcoma continues to
       contribute substantially to the morbidity suffered by AIDS patients.
       Advances in our understanding of the pathogenesis of Kaposi's sarcoma
       have resulted in treatment strategies that are being investigated in the
       laboratory and clinic. Agents that affect the abnormal cytokines
       associated with Kaposi's sarcoma or inhibit angiogenesis are in early
       clinical trials. The recent discovery of a putative Kaposi's sarcoma
       virus may lead to new preventive or therapeutic strategies. Interferon,
       usually in combination with an antiretroviral nucleoside analogue,
       remains an important therapeutic option for patients with relatively
       intact immune function. For patients with more advanced immune
       suppression, chemotherapy is usually given, although there is no
       standard treatment regimen. New chemotherapeutic agents, including the
       use of liposomal encapsulated anthracyclines and topoisomerase-1
       inhibitors, are being evaluated.
 DE    Antineoplastic Agents/ADMINISTRATION & DOSAGE/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/MICROBIOLOGY  Clinical Trials
       Drug Carriers  Gene Products, tat/ANTAGONISTS & INHIB/PHYSIOLOGY  Genes,
       tat  Human  HIV Infections/*COMPLICATIONS  Interferons/THERAPEUTIC USE
       Liposomes  Neovascularization, Pathologic  Palliative Care  Sarcoma,
       Kaposi's/ETIOLOGY/PATHOLOGY/PHYSIOPATHOLOGY/*THERAPY  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

